ARROW: pralsetinib for RET fusion-positive non-small-cell lung cancer
Pralsetinib, a second selective RET inhibitor, shrank tumours in 61 percent of previously treated and 70 percent of untreated patients with RET fusion-positive lung cancer, giving an alternative to selpercatinib.
Overview
Phase 1/2 study including 233 patients with RET fusion-positive non-small-cell lung cancer treated with pralsetinib 400 mg daily.
Objective response was 61 percent in patients previously treated with platinum chemotherapy and 70 percent in treatment-naive patients, with median duration of response not reached in the latter; neutropenia, hypertension and liver enzyme rise were common.
- Objective response 61 percent (previously treated) and 70 percent (treatment-naive).
- Grade 3 or worse neutropenia in about 18 percent.
Pralsetinib is approved for RET fusion-positive lung cancer and is used where selpercatinib is unavailable or not tolerated.
- Single-arm; pneumonitis and haematological toxicity more frequent than with selpercatinib in cross-trial comparison.
Similar pages
not linked directly; found by shared links- PersonJustin F. Gainor
Shares Pralsetinib, RET fusion-positive non-small-cell lung cancer.
- CompanyBlueprint Medicines
Shares Pralsetinib, RET fusion-positive non-small-cell lung cancer.
- TreatmentSelpercatinib
Shares Pralsetinib, RET fusion-positive non-small-cell lung cancer.
- PathwayNon-small cell lung cancer (KEGG map)
Shares Pralsetinib, RET fusion-positive non-small-cell lung cancer.